AAN: Race May Affect Response to Anti-CD20 Therapy for MS, NMOSD
B-cell repopulation occurs more often in African American vs White patients between 6 and 12 months after anti-CD20 infusion
Miscellaneous Neurodegenerative Disorders
Considerable Neurologic, Psychiatric Morbidity Reported After COVID-19
Estimated incidence of neurological or psychiatric diagnosis was 33.62 percent among 236,379 patients
New Symptoms Common 4 Months After COVID-19
Half of patients declared at least one symptom that did not exist before COVID-19, most commonly fatigue, cognitive symptoms, dyspnea
Neurologic Involvement Common in Children Hospitalized With COVID-19
Twelve percent of those with neurologic involvement develop life-threatening conditions associated with COVID-19
MPR Weekly Dose Podcast 70
This week we have news of an indication for the cancer treatment, Keytruda, being withdrawn; Janssen’s single dose vaccine gains Emergency Use Authorization; There’s findings on the effectiveness of ivermectin as a therapy for mild COVID-19; And devices to treat migraine and prevention of sub-concussive head impacts are authorized for marketing.
FDA to Review Efgartigimod for Generalized Myasthenia Gravis
Efgartigimod, an Fc receptor antagonist, reduces disease-causing immunoglobulin G (IgG) antibodies and blocks the IgG recycling process.
Cerliponase Alfa May Slow Developmental Function Decline in CLN2 Disease
Cerliponase alfa demonstrates a slower rate of decline of developmental skills in patients with CLN2 disease compared to a natural history cohort.
Brain-Eating Amoeba Found in Tap Water of Lake Jackson, Texas
Infection can occur when Naegleria fowleri-contaminated water enters body through the nose.
Florida Teen Dies From Brain-Eating Amoeba
Naegleria fowleri can get into the brain when contaminated water enters the nose.
Enspryng, a Self-Administered Treatment for NMOSD, Gets FDA Approval
The FDA has approved Enspryng (satralizumab-mwge; Genentech) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
